The landscape of managing diabetes is changing with the arrival of transdermal GLP-1 delivery . These convenient delivery systems offer a likely simpler alternative to shots for individuals living with diabetes mellitus type 2 . Such a system deliver a GLP-1 agonist directly through the epidermis